SELLAS (SLS) Ranks Among Top 10 U.S. Stocks in June 2026 Amid Clinical Trial Success and Analyst Upgrade

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) emerged as one of the top 10 performing American stocks in June 2026, driven by promising clinical trial outcomes and an upgraded price target from Alliance Global analyst James Molloy. The firm raised its target from $10 to $25, citing the delayed release of top-line data from the REGAL Phase 3 trial in acute myeloid leukemia (AML) patients as a potential positive indicator. As of May 11, 2026, 78 of the 80 required events had occurred in the trial, suggesting patients may be surviving longer than expected on Best Available Therapy in the CR2 AML setting.

Clinical Trial Milestone Sparks Analyst Confidence

■The REGAL trial, which requires 80 events to trigger database lock and unblinding, is nearing completion with only two deaths remaining.

■The SLS009 Phase 2 trial in newly diagnosed AML patients, launched in May, is poised to deliver topline data by Q4 2026.

■Analysts interpret the trial’s prolonged survival data as a bullish signal for the company’s pipeline.

Financial Strategy and Market Positioning

■SELLAS established an ATM equity offering under its S-3ASR shelf registration, enabling up to $150 million in potential capital raises.

■CEO Angelos Stergiou emphasized the first quarter as a pivotal period for advancing clinical programs ahead of the REGAL trial readout.

■The company has not sold any shares through the ATM program as of the latest update.

Captain Rıza Deniz Note: SELLAS’s clinical progress reflects the high-risk, high-reward dynamics typical of the biotech sector. While the delayed trial data may signal efficacy, the broader implications for global pharmaceutical supply chains and U.S. onshoring policies under Trump-era tariffs remain understated. Investors should weigh these developments against macroeconomic headwinds affecting R&D funding and regulatory timelines.